Immuno-Gene Therapy Committee, International Society for Cell and Gene Therapy; Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, Arizona, USA.
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.
Cytotherapy. 2023 Jan;25(1):20-32. doi: 10.1016/j.jcyt.2022.10.002. Epub 2022 Oct 22.
The field of cell and gene therapy in oncology has moved rapidly since 2017 when the first cell and gene therapies, Kymriah followed by Yescarta, were approved by the Food and Drug Administration in the United States, followed by multiple other countries. Since those approvals, several new products have gone on to receive approval for additional indications. Meanwhile, efforts have been made to target different cancers, improve the logistics of delivery and reduce the cost associated with novel cell and gene therapies. Here, we highlight various cell and gene therapy-related technologies and advances that provide insight into how these new technologies will speed the translation of these therapies into the clinic.
In this review, we provide a broad overview of the current state of cell and gene therapy-based approaches for cancer treatment - discussing various effector cell types and their sources, recent advances in both CAR and non-CAR genetic modifications, and highlighting a few promising approaches for increasing in vivo efficacy and persistence of therapeutic drug products.
自 2017 年美国食品和药物管理局 (FDA) 批准了首个细胞和基因疗法——Kymriah 和 Yescarta 以来，肿瘤学领域的细胞和基因治疗发展迅速，随后多个国家也批准了这两种疗法。自这些批准以来，又有几种新产品获得了其他适应症的批准。与此同时，人们还努力针对不同的癌症，改进递送的物流，并降低新型细胞和基因疗法的相关成本。在这里，我们重点介绍了各种与细胞和基因治疗相关的技术和进展，这些技术和进展为这些新技术如何加速将这些疗法转化为临床应用提供了深入了解。
在这篇综述中，我们广泛概述了基于细胞和基因治疗的癌症治疗方法的现状——讨论了各种效应细胞类型及其来源、CAR 和非 CAR 基因修饰的最新进展，并强调了几种提高治疗性药物产品体内疗效和持久性的有前途的方法。
